Pearl River Capital’s Amicus Therapeutics FOLD Stock Holding History

Pearl River Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-20,954	Closed	-$256K	–	536
2022 Q4	$256K	Sell	20,954 -5,180	-20%	-$58.3K	0.04%	438
2022 Q3	$273K	Buy	+26,134	New	+$291K	0.05%	388
2020 Q3	–	Sell	-14,270	Closed	-$215K	–	389
2020 Q2	$215K	Buy	+14,270	New	+$174K	0.11%	245
2019 Q1	–	Sell	-999	Closed	-$10K	–	491
2018 Q4	$10K	Buy	+999	New	+$11K	0.05%	545

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Pearl River Capital's FOLD Position: Q1 2023 in Review

Pearl River Capital sold out of Amicus Therapeutics (FOLD) in Q1 2023, closing a stake of 20,954 shares — an estimated $256K sold.

Pearl River Capital first reported a position in FOLD in Q4 2018 and held it in 4 quarters. The position peaked at $273K in Q3 2022. 226 funds tracked by Wall St. Rank hold FOLD as of Q1 2023.

Pearl River Capital reported no remaining Amicus Therapeutics position as of Q1 2023 after selling out during the quarter.
Pearl River Capital sold 20,954 Amicus Therapeutics shares in Q1 2023, an estimated $256K.
Pearl River Capital first reported a position in Amicus Therapeutics in Q4 2018 and held it in 4 quarters.
Pearl River Capital's Amicus Therapeutics position peaked at $273K in Q3 2022.
226 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2023.

Based on Pearl River Capital's 13F filing for Q1 2023, filed 12 May 2023.